| Drug Name: | Amitriptyline (50-48-6) |
|---|---|
| PubChem ID: | 2160 |
| SMILES: | CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31 |
| InchiKey: | KRMDCWKBEZIMAB-UHFFFAOYSA-N |
| Therapeutic Category: | Adrenergic Agents, Adrenergic Uptake Inhibitors, Analgesics, Antidepressive Agents, Central Nervous System Agents, Membrane Transport Modulators, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Peripheral Nervous System Agents, Psychotropic Drugs, Sensory System Agents |
| Molecular Weight (dalton) | : | 277.411 |
| LogP | : | 4.1686 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 1 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 3.24 |
This panel provides information on interacting drugs and their ADRs along with references
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Arrhythmia | CYP2D6 (P10635) | Cholestyramine(CYP2D6 substrate) increases enterohepatic elimination of amiodarone and may reduce its serum levels and t?. Disopyramide increases QT prolongation which could cause arrhythmia. [ ADR Type 4 ] | Comment: potential risk of valproic acid therapy in patients who are HIV-positive |
| Bradycardia | Cytochrome P450 3A4 (P08684) | Amiodarone should be used with caution in patients receiving ?-receptor blocking agents (e.g.@ propranolol@ a CYP3A4 inhibitor) or calcium channel antagonists (e.g.@ verapamil@ a CYP3A4 substrate@ and diltiazem@ a CYP3A4 inhibitor) because of the possible potentiation of bradycardia@ sinus arrest@ and AV block; if necessary@ amiodarone can continue to be used after insertion of a pacemaker in patients with severe bradycardia or sinus arrest. [ ADR Type 4 ] | Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs |
| Elevated Creatinine | Cytochrome P450 3A4 (P08684) | Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine@ despite reduction in dose of cyclosporine [ ADR Type 4 ] | Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs |
| Fatal Bleeding | Cytochrome P450 2C19 (P33261) | Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days@ the dose of the anticoagulant should be reduced by one-third to one-half@ and prothrombin times should be monitored closely A similar effect has been reported with fluindione@ an oral vitamin K antaGOnist@ when administered concomitantly with Cordarone [ ADR Type 4 ] | Nonspecific factors and side effect complaints Factors affecting the incidence of drowsiness in drug and placebo treated anxious and depressed outpatients |
| Ineffective Inhibition Of Platelet Aggregation | Cytochrome P450 3A4 (P08684) | Clopidogrel@ an inactive thienopyridine prodrug@ is metabolized in the liver by CYP3A4 to an active metabolite A potential interaction between clopidogrel and Cordarone resulting in ineffective inhibition of platelet aggregation has been reported [ ADR Type 4 ] | Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs |
| Rhabdomyolysis | Cytochrome P450 3A4 (P08684) | Simvastatin (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis [ ADR Type 4 ] | Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category